Can we approach zero relapse in breast cancer?

Oncologist

Volumn 10, Issue SUPPL. 2, 2005, Pages 9-17

  Mamounas, Eleftherios P ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Genomic profiling; Neoadjuvant therapy; Taxanes; Trastuzumab

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB;

BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUING EDUCATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENOMICS; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; ONCOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SENTINEL LYMPH NODE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; NEOADJUVANT THERAPY; PROGNOSIS; RECURRENCE;

EID: 28044461227     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.10-90002-9     Document Type: Conference Paper

References (39)

1. Peto R, Boreham J, Clarke M et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
2. Early Breast Cancer Trialists' Collborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Chung CT, Carlson RW. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? Clin Breast Cancer 2004;5(suppl 1):S18-S23.
4. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
5. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-3696.
6. Roche H, Fumoleau P, Speilmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004;88(suppl 1):S16.
7. Martin M, Pienkovvski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
8. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. The Oncologist 2001;6:376-385.
9. Romond EH, Perez EA, Bryant J et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Joint analysis of NSABP-B-31 and NCCTG-N9831. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005.
10. Perez EA, Suman VJ, Davidson NE et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, Florida, May 14-17, 2005.
11. Martine J. Piccart-Gebhart, on behalf of The Breast International Group (BIG). NON-BIG participating groups, Independent sites, F. Hoffmann-La Roche Ltd. First Results of the HER A trial. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005.
12. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as apredictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
13. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
14. Paik S, Shak S, Gong, T et al. Expression of the 21 genes in the Recurrence Score assay and prediction of the clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 2004;88(suppl 1):S15.
15. Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffin-embedded core biopsy tissue predictresponse to chemotherapy in patients with locally advanced breast cancer. J Clin Oncol 2005; 23 (in press).
16. Trudeau M, Sinclair SE, Clemons M. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 2005;31:283-302.
17. Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer 2003;4(suppl 1):S10-S19.
18. Fisher B, Jeong JH, Bryant J et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-868.
19. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
20. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
21. Thurlimann BJ, Keshaviah A, Mouridsen H et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, Florida, May 14-17, 2005:511a.
22. Boccardo FM, Rubagotti A, Puntoni M et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005:526a.
23. Coombes RC, Hall E, Snowdon CF et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;88(suppl 1):S7.
24. Jakesz R, Kaufman M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88(suppl 1):S7.
25. Goss PE, Ingle JN, Martino S et al. Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 2004;22(suppl 14):847a.
26. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a(ABCSG-6a). Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005:527a.
27. Fisher B, Jeong JH, Anderson S et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96:1823-1831.
28. Goldstein L, O'Neill A, Sparano J et al. E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005:512a.
29. Bear HD, Anderson S, Smith RE et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 2004;88(suppl 1):S16.
30. Swain SM, Land SR, Sundry R et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) Æ docetaxel (T) arm of NSABPB-30: preliminary results. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14-17, 2005, 537a.
31. Citron ML, Berry DA, Cirrincione C et al. Randomized trialof dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
32. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001:96-102.
33. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Study Group. J Clin Oncol 2005;23:2676-2685.
34. Untch M, Kochecny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. J Clin Oncol 2002;21:34a.
35. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
36. Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005;23:2988-2995.
37. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission i n operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
38. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
39. Buzdar AU, Hunt K, Smith T et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. J Clin Oncol 2004;22(suppl 14):520a.